Table 3 Hazard ratios for 5-year local recurrence-free survival after radiotherapy plus carbogen and nicotinamide compared with radiotherapy alone
Variable | HR | 95% CI | P -value |
|---|---|---|---|
HIF-1 α ⩾19 | 0.48 | 0.26–0.80 | 0.02 |
HIF-1α <19 | 0.81 | 0.43−1.50 | 0.5 |
CAIX >0 | 0.47 | 0.28–0.81 | 0.006 |
CAIX=0 | 0.81 | 0.43−1.50 | 0.5 |
GLUT1 ⩾100 | 0.56 | 0.31−1.03 | 0.06 |
GLUT <100 | 0.62 | 0.32−1.20 | 0.15 |
HIF-1 α ⩾19+CAIX >0 | 0.38 | 0.18–0.79 | 0.01 |
HIF-1α <19 or CAIX=0 | 0.74 | 0.43−1.28 | 0.29 |
CAIX >0+GLUT1 ⩾0 | 0.47 | 0.23–0.95 | 0.03 |
CAIX=0 or GLUT1 <100 | 0.64 | 0.35−1.15 | 0.13 |
HIF-1α ⩾19+GLUT1 ⩾100 | 0.49 | 0.23−1.05 | 0.06 |
HIF-1α <19 or CAIX=0 | 0.69 | 0.40−1.21 | 0.2 |
Necrosis present | 0.46 | 0.29–0.73 | 0.001 |
Necrosis absent | 1.37 | 0.81−2.30 | 0.24 |
Necrosis present+HIF-1 α ⩾19 | 0.36 | 0.16–0.79 | 0.01 |
Necrosis absent or HIF-1α <19 | 0.82 | 0.49−1.38 | 0.45 |
Necrosis present+CAIX >0 | 0.47 | 0.25–0.89 | 0.02 |
Necrosis absent or CAIX=0 | 0.77 | 0.43−1.38 | 0.38 |
Necrosis present+GLUT1 ⩾100 | 0.37 | 0.17–0.80 | 0.01 |
Necrosis absent+GLUT1 <100 | 0.89 | 0.50−1.58 | 0.69 |
